{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:21:56Z","timestamp":1793823716542,"version":"4.6.1"},"reference-count":137,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017530","name":"Fresenius HemoCare GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.semarthrit.2025.152740","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T20:23:43Z","timestamp":1745958223000},"page":"152740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-218X","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest","family":"Choy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10416","key":"10.1016\/j.semarthrit.2025.152740_bib0001","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semarthrit.2014.05.001","article-title":"The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis","volume":"44","author":"Matcham","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152740_bib0003","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/rheumatology\/kew243","article-title":"Tight control of disease activity fails to improve body composition or physical function in rheumatoid arthritis patients","volume":"55","author":"Lemmey","year":"2016","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0280846","article-title":"Changes in physical function over time in rheumatoid arthritis patients: a cohort study","volume":"18","author":"Santo","year":"2023","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0005","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/ar2951","article-title":"Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from 32 countries in the QUEST-RA study","volume":"12","author":"Sokka","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0006","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/rheumatology\/key013","article-title":"Rheumatoid arthritis and excess mortality: down but not out. A primary care cohort study using data from Clinical Practice Research Datalink","volume":"57","author":"Abhishek","year":"2018","journal-title":"Rheumatol (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","article-title":"Mortality in rheumatoid arthritis over the last fifty years: systematic review and meta-analysis","volume":"80","author":"Dadoun","year":"2013","journal-title":"Joint Bone Spine"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152740_bib0008","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1002\/art.22979","article-title":"The widening mortality gap between rheumatoid arthritis patients and the general population","volume":"56","author":"Gonzalez","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0009","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0010","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9343(01)00872-5","article-title":"Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies","volume":"111","author":"Lard","year":"2001","journal-title":"Am J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0011","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1136\/ard.2003.010298","article-title":"Radiological outcome after four years of early versus delayed treatment strategy in patients with recent onset rheumatoid arthritis","volume":"63","author":"van Aken","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000870","article-title":"Window of opportunity in rheumatoid arthritis - definitions and supporting evidence: from old to new perspectives","volume":"5","author":"Burgers","year":"2019","journal-title":"RMD Open"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/s41584-019-0170-5","article-title":"Treat-to-target in rheumatoid arthritis - are we there yet?","volume":"15","author":"van Vollenhoven","year":"2019","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0014","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3831\/KPI.2019.22.029","article-title":"Rheumatiod Arthritis: an Updated Overview of Latest Therapy and Drug Delivery","volume":"22","author":"Kesharwani","year":"2019","journal-title":"J Pharmacopuncture"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0015","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0017","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.coph.2022.102234","article-title":"A review of biosimilars for rheumatoid arthritis","volume":"64","author":"Conran","year":"2022","journal-title":"Curr Opin Pharmacol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001637","article-title":"Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects","volume":"7","author":"Smolen","year":"2021","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0020","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1136\/annrheumdis-2011-200274","article-title":"A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry","volume":"71","author":"Schipper","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0021","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ker355","article-title":"Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial","volume":"51","author":"van Eijk","year":"2012","journal-title":"Rheumatol (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0022","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","article-title":"Defining refractory rheumatoid arthritis","volume":"77","author":"Buch","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0023","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"British Society for Rheumatology Biologics R. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0024","article-title":"Precision Medicine for Rheumatoid Arthritis: the Right Drug for the Right Patient-Companion Diagnostics","volume":"11","author":"Meehan","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152740_bib0025","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","article-title":"Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis","volume":"41","author":"Khader","year":"2022","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0026","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1136\/ard-2023-225014","article-title":"Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0027","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/acr.21768","article-title":"Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine","volume":"65","author":"Gremese","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0028","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1111\/bcp.13192","article-title":"Is there potential for therapeutic drug monitoring of biologic agents in rheumatoid arthritis?","volume":"83","author":"Bastida","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0029","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/17425255.2017.1360280","article-title":"Biological anti-TNF drugs: immunogenicity underlying treatment failure and adverse events","volume":"13","author":"Prado","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152740_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40262-015-0296-9","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis","volume":"54","author":"Ternant","year":"2015","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0031","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.dld.2022.07.012","article-title":"Efficacy and safety of combination targeted therapies in immune-mediated inflammatory disease: the COMBIO study","volume":"55","author":"Guillo","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0032","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1340764","article-title":"Therapeutic evolution in HR+\/HER2- breast cancer: from targeted therapy to endocrine therapy","volume":"15","author":"Cao","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0033","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"5 Suppl 85","key":"10.1016\/j.semarthrit.2025.152740_bib0034","article-title":"Scores for all seasons: SDAI and CDAI","volume":"32","author":"Smolen","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0035","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fmed.2018.00185","article-title":"The Utility and Limitations of CRP, ESR and DAS28-CRP in Appraising Disease Activity in Rheumatoid Arthritis","volume":"5","author":"Orr","year":"2018","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0036","doi-asserted-by":"crossref","first-page":"R40","DOI":"10.1186\/ar4469","article-title":"Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year","volume":"16","author":"Kay","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0037","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3899\/jrheum.080770","article-title":"Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States","volume":"36","author":"Sokka","year":"2009","journal-title":"J Rheumatol"},{"issue":"5 Suppl 39","key":"10.1016\/j.semarthrit.2025.152740_bib0038","first-page":"S100","article-title":"The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis","volume":"23","author":"Aletaha","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0039","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/325909","article-title":"The Role of Power Doppler Ultrasonography as Disease Activity Marker in Rheumatoid Arthritis","volume":"2015","author":"Bhasin","year":"2015","journal-title":"Dis Markers"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0040","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/rheumatology\/keq415","article-title":"The power Doppler ultrasonography score from 24 synovial sites or 6 simplified synovial sites, including the metacarpophalangeal joints, reflects the clinical disease activity and level of serum biomarkers in patients with rheumatoid arthritis","volume":"50","author":"Kawashiri","year":"2011","journal-title":"Rheumatol (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0041","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0203607","article-title":"Linking systemic angiogenic markers to synovial vascularization in rheumatoid arthritis","volume":"13","author":"Leblond","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0042","doi-asserted-by":"crossref","first-page":"rkz002","DOI":"10.1093\/rap\/rkz002","article-title":"Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review","volume":"3","author":"Edwards","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001025","article-title":"From bench to bedside: calprotectin (S100A8\/S100A9) as a biomarker in rheumatoid arthritis","volume":"13","author":"Inciarte-Mundo","year":"2022","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0044","doi-asserted-by":"crossref","first-page":"760","DOI":"10.3899\/jrheum.140628","article-title":"Calprotectin as a biomarker for rheumatoid arthritis: a systematic review","volume":"42","author":"Abildtrup","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0045","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/00325481.2017.1319729","article-title":"Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis","volume":"129","author":"Bae","year":"2017","journal-title":"Postgrad Med"},{"issue":"17","key":"10.1016\/j.semarthrit.2025.152740_bib0046","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2217\/bmm-2022-0216","article-title":"Linkage of calprotectin with inflammation, activity and treatment response of rheumatoid arthritis: a meta-analysis","volume":"16","author":"Zeng","year":"2022","journal-title":"Biomark Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0047","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s10067-018-4091-5","article-title":"Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein","volume":"37","author":"Hurnakova","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0048","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13075-016-1032-z","article-title":"Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity","volume":"18","author":"Inciarte-Mundo","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0049","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-020-02190-3","article-title":"Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis","volume":"22","author":"Jarlborg","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152740_bib0050","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1136\/annrheumdis-2017-211695","article-title":"Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis","volume":"76","author":"Jonsson","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0051","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/art.41701","article-title":"Semaphorins: from Angiogenesis to Inflammation in Rheumatoid Arthritis","volume":"73","author":"Avouac","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0052","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s41927-017-0001-8","article-title":"Cytokines in the pathogenesis of rheumatoid arthritis: new players and therapeutic targets","volume":"1","author":"Alunno","year":"2017","journal-title":"BMC Rheumatol"},{"issue":"20","key":"10.1016\/j.semarthrit.2025.152740_bib0053","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010922","article-title":"Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis","volume":"22","author":"Kondo","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0054","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/BOR.0000000000000470","article-title":"What are the dominant cytokines in early rheumatoid arthritis?","volume":"30","author":"Ridgley","year":"2018","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0055","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s10067-018-4379-5","article-title":"Evaluation of cytokine profiles in rheumatoid arthritis patients with clinically active disease and normal inflammatory indices","volume":"38","author":"Alex","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0056","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246111","article-title":"Potential applicability of cytokines as biomarkers of disease activity in rheumatoid arthritis: enzyme-linked immunosorbent spot assay-based evaluation of TNF-alpha, IL-1beta, IL-10 and IL-17A","volume":"16","author":"Dissanayake","year":"2021","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060635","article-title":"Development of a multi-biomarker disease activity test for rheumatoid arthritis","volume":"8","author":"Centola","year":"2013","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152740_bib0058","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/acr.21767","article-title":"Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity","volume":"64","author":"Curtis","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0059","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13075-020-02240-w","article-title":"A multi-biomarker disease activity score can predict sustained remission in rheumatoid arthritis","volume":"22","author":"Ma","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0060","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1093\/rheumatology\/kes362","article-title":"A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study","volume":"52","author":"Hirata","year":"2013","journal-title":"Rheumatol (Oxford)"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0061","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/14397595.2014.958893","article-title":"A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: a retrospective observational study","volume":"25","author":"Hirata","year":"2015","journal-title":"Mod Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0062","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/art.39714","article-title":"Brief Report: estimating Disease Activity Using Multi-Biomarker Disease Activity Scores in Rheumatoid Arthritis Patients Treated With Abatacept or Adalimumab","volume":"68","author":"Fleischmann","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0063","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002423","article-title":"Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis","volume":"8","author":"Kay","year":"2022","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0064","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00296-015-3285-2","article-title":"Interpreting the multi-biomarker disease activity score in the context of tocilizumab treatment for patients with rheumatoid arthritis","volume":"36","author":"Reiss","year":"2016","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-010423","article-title":"C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab","volume":"2013","author":"Bari","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0066","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/s10165-008-0111-7","article-title":"Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0067","article-title":"The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment","volume":"2012","author":"Yanagawa","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0068","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152740_bib0069","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1007\/s10067-019-04684-1","article-title":"Defining response to TNF-inhibitors in rheumatoid arthritis: the negative impact of anti-TNF cycling and the need for a personalized medicine approach to identify primary non-responders","volume":"38","author":"Johnson","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0070","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.mayocp.2017.05.009","article-title":"Prediction of Response to Targeted Treatment in Rheumatoid Arthritis","volume":"92","author":"Wijbrandts","year":"2017","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0071","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0300-483X(98)00063-8","article-title":"Cytokine assays in human sera and tissues","volume":"129","author":"Bienvenu","year":"1998","journal-title":"Toxicology"},{"issue":"Pt 4","key":"10.1016\/j.semarthrit.2025.152740_bib0072","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/000456329503200402","article-title":"Factors affecting the measurement of cytokines in biological fluids: implications for their clinical measurement","volume":"32","author":"Heney","year":"1995","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0073","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2249.1998.00641.x","article-title":"Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production","volume":"113","author":"O'Mahony","year":"1998","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0074","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF02592351","article-title":"Preanalytical factors and the measurement of cytokines in human subjects","volume":"26","author":"Dugue","year":"1996","journal-title":"Int J Clin Lab Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0075","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.4049\/jimmunol.173.9.5343","article-title":"Mechanisms of soluble cytokine receptor generation","volume":"173","author":"Levine","year":"2004","journal-title":"J Immunol"},{"issue":"1\u20132","key":"10.1016\/j.semarthrit.2025.152740_bib0076","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-1759(98)00093-3","article-title":"Cytokine immunoassays: recommendations for standardisation, calibration and validation","volume":"219","author":"Wadhwa","year":"1998","journal-title":"J Immunol Methods"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0077","first-page":"115","article-title":"Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge","volume":"12","author":"Oliver","year":"1993","journal-title":"Lymphokine Cytokine Res"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0078","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2010-08-265892","article-title":"Cytokine release from innate immune cells: association with diverse membrane trafficking pathways","volume":"118","author":"Lacy","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0079","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000084844","article-title":"IL-6 and its circadian secretion in humans","volume":"12","author":"Vgontzas","year":"2005","journal-title":"Neuroimmunomodulation"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152740_bib0080","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.5858\/arpa.2019-0519-CP","article-title":"Rhoads DD. Variability in the Laboratory Measurement of Cytokines","volume":"144","author":"Knight","year":"2020","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0081","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1002\/art.11098","article-title":"Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue","volume":"48","author":"Smeets","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0082","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/art.1780390702","article-title":"Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis","volume":"39","author":"Tak","year":"1996","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0083","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003199","article-title":"IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis","volume":"3","author":"Wang","year":"2013","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0084","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s10067-016-3306-x","article-title":"Inflammatory cytokine levels, disease activity, and function of patients with rheumatoid arthritis treated with combined conventional disease-modifying antirheumatic drugs or biologics","volume":"35","author":"Osiri","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0085","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1002\/art.41299","article-title":"Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis","volume":"72","author":"Boyapati","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0086","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13075-020-02344-3","article-title":"High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0087","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kev421","article-title":"Personalized biological treatment for rheumatoid arthritis: a systematic review with a focus on clinical applicability","volume":"55","author":"Cuppen","year":"2016","journal-title":"Rheumatol (Oxford)."},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0088","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1089\/jir.2023.0078","article-title":"Serum Cytokine Profiles in Patients with Rheumatoid Arthritis Before and After Treatment with Methotrexate","volume":"43","author":"Lama","year":"2023","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0089","series-title":"EULAR Conference, Vienna, Austria, June 12\u201315 2024","article-title":"Altered serum inflammatory and angiogenic signatures in refractory rheumatoid arthritis [Conference abstract]","author":"Lesturgie-Talarek","year":"2024"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0090","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2014.04.006","article-title":"Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples","volume":"408","author":"Bastarache","year":"2014","journal-title":"J Immunol Methods"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0091","doi-asserted-by":"crossref","DOI":"10.3390\/jpm10040202","article-title":"Contribution of Multiplex Immunoassays to Rheumatoid Arthritis Management: from Biomarker Discovery to Personalized Medicine","volume":"10","author":"Laborde","year":"2020","journal-title":"J Pers Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0092","first-page":"1801","article-title":"Plasma levels of multiple cardiovascular- and inflammation-related proteins analysed for associations with disease activity and anti-cyclic citrullinated peptide status in active early rheumatoid arthritis","volume":"41","author":"Masic","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0093","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-016-0106-4","article-title":"Immune Monitoring Technology Primer: protein microarray ('seromics')","volume":"4","author":"Yuan","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0094","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1021\/acs.analchem.9b04403","article-title":"CRISPR\/Cas13a Signal Amplification Linked Immunosorbent Assay for Femtomolar Protein Detection","volume":"92","author":"Chen","year":"2020","journal-title":"Anal Chem"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0095","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/rheumatology\/kel237","article-title":"Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease","volume":"46","author":"Machold","year":"2007","journal-title":"Rheumatol (Oxford)"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0096","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/art.20018","article-title":"Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors","volume":"50","author":"Nielen","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2025.152740_bib0097","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantapaa-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0098","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/nrrheum.2017.15","article-title":"Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis","volume":"13","author":"Trouw","year":"2017","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0099","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/rheumatology\/40.2.205","article-title":"Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes","volume":"40","author":"Edwards","year":"2001","journal-title":"Rheumatol (Oxford)"},{"issue":"25","key":"10.1016\/j.semarthrit.2025.152740_bib0100","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0101","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0102","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2012.11.007","article-title":"Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: systematic review and meta-analysis","volume":"43","author":"Maneiro","year":"2013","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0103","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0104","doi-asserted-by":"crossref","unstructured":"Conti V., Corbi G., Costantino M., De Bellis E., Manzo V., Sellitto C., et al. Biomarkers to Personalize Treatment Rheumatoid Arthritis 2020;10(12). Epub 20201214. doi: 10.3390\/biom10121672. PubMed PMID: 33327600; PubMed Central PMCID: PMC7765045.","DOI":"10.3390\/biom10121672"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0105","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization\u2013a step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatol (Oxford)"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0106","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040362","article-title":"Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis","volume":"7","author":"Ferraccioli","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0107","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0128269","article-title":"Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response","volume":"10","author":"Adlowitz","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1100869","article-title":"Chemokines and chemokine receptors as promising targets in rheumatoid arthritis","volume":"14","author":"Murayama","year":"2023","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0109","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1002\/art.38023","article-title":"CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis","volume":"65","author":"Sellam","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0110","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1186\/s13075-014-0434-z","article-title":"CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic 'window of opportunity","volume":"16","author":"Greisen","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0111","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s13075-016-0995-0","article-title":"Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study","volume":"18","author":"Han","year":"2016","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0112","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.081074","article-title":"Correlation of CX3CL1 and CX3CR1 levels with response to infliximab therapy in patients with rheumatoid arthritis","volume":"36","author":"Odai","year":"2009","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2025.152740_bib0113","first-page":"956","article-title":"Serum CXCL10 levels are associated with better responses to abatacept treatment of rheumatoid arthritis","volume":"38","author":"Yukawa","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0114","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar4555","article-title":"Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics","volume":"16","author":"Dennis","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0115","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s10067-020-05043-1","article-title":"The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs","volume":"39","author":"Zhao","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0116","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s41927-020-00154-3","article-title":"A systematic review of CXCL13 as a biomarker of disease and treatment response in rheumatoid arthritis","volume":"4","author":"Bechman","year":"2020","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0117","first-page":"1","article-title":"Clinical validation of a blood-based predictive test for stratification of response to tumor necrosis factor inhibitor therapies in rheumatoid arthritis patients","volume":"3","author":"Mellors","year":"2020","journal-title":"Network Syst Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2025.152740_bib0118","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1007\/s40744-021-00330-y","article-title":"A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-alpha Inhibitors: the NETWORK-004 Prospective Observational Study","volume":"8","author":"Cohen","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/14737159.2022.2020648","article-title":"Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor-a inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis","volume":"22","author":"Strand","year":"2022","journal-title":"Expert Rev Mol Diagn"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0120","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14712598.2022.2066972","volume":"22","author":"Strand","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0121","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra2103726","article-title":"Rheumatoid Arthritis - Common Origins, Divergent Mechanisms","volume":"388","author":"Gravallese","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0122","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41590-019-0378-1","article-title":"Defining inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-cell transcriptomics and mass cytometry","volume":"20","author":"Zhang","year":"2019","journal-title":"Nat Immunol"},{"issue":"8","key":"10.1016\/j.semarthrit.2025.152740_bib0123","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0124","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/annrheumdis-2016-210424","article-title":"Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?","volume":"76","author":"Alivernini","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.semarthrit.2025.152740_bib0125","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1002\/art.42295","article-title":"Synovial Inflammatory Pathways Characterize Anti-TNF-Responsive Rheumatoid Arthritis Patients","volume":"74","author":"Wang","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2025.152740_bib0126","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10067-022-06438-y","article-title":"Predictors of response of rituximab in rheumatoid arthritis by weighted gene co-expression network analysis","volume":"42","author":"Zhang","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2025.152740_bib0127","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41467-018-02892-y","article-title":"Functionally distinct disease-associated fibroblast subsets in rheumatoid arthritis","volume":"9","author":"Mizoguchi","year":"2018","journal-title":"Nat Commun"},{"issue":"7760","key":"10.1016\/j.semarthrit.2025.152740_bib0128","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/s41586-019-1263-7","article-title":"Distinct fibroblast subsets drive inflammation and damage in arthritis","volume":"570","author":"Croft","year":"2019","journal-title":"Nature"},{"issue":"7811","key":"10.1016\/j.semarthrit.2025.152740_bib0129","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-020-2222-z","article-title":"Notch signalling drives synovial fibroblast identity and arthritis pathology","volume":"582","author":"Wei","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.semarthrit.2025.152740_bib0130","unstructured":"Zou A., Kongthong S., Murphy C., Watts G., Mueller A., Brenner M. Arid5b controls pathologic inflammatory versus invasive fibroblast behavior [Conference abstract]. Arthritis rheumatol [Internet].Accessed 6 December 2024. https:\/\/acrabstracts.org\/abstract\/arid5b-controls-pathologic-inflammatory-versus-invasive-fibroblast-behavior\/."},{"issue":"7","key":"10.1016\/j.semarthrit.2025.152740_bib0131","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.medj.2022.05.002","article-title":"Cross-tissue, single-cell stromal atlas identifies shared pathological fibroblast phenotypes in four chronic inflammatory diseases","volume":"3","author":"Korsunsky","year":"2022","journal-title":"Med"},{"issue":"10271","key":"10.1016\/j.semarthrit.2025.152740_bib0132","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0133","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41591-022-01789-0","article-title":"Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial","volume":"28","author":"Rivellese","year":"2022","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2025.152740_bib0134","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1016\/S2665-9913(23)00241-2","article-title":"Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials","volume":"5","author":"Rivellese","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2025.152740_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8060826","article-title":"The Potential Role of Genomic Medicine in the Therapeutic Management of Rheumatoid Arthritis","volume":"8","author":"Acosta-Herrera","year":"2019","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2025.152740_bib0136","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3390\/biom10091203","article-title":"Polymorphisms Involved in Response to Biological Agents Used in Rheumatoid Arthritis","volume":"10","author":"Pallio","year":"2020","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.semarthrit.2025.152740_bib0137","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10456-015-9477-2","article-title":"The pathogenic role of angiogenesis in rheumatoid arthritis","volume":"18","author":"Elshabrawy","year":"2015","journal-title":"Angiogenesis"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017225001118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T03:57:18Z","timestamp":1762228638000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017225001118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":137,"alternative-id":["S0049017225001118"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152740","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalised treatment of rheumatoid arthritis based on cytokine profiles and synovial tissue signatures: potentials and challenges","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2025.152740","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152740"}}